Logo Repligen

Repligen (RGEN) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Repligen · Health Care · ref. ETF XLV · 57 calls · price $175.42
💬JPI AI AssistantTry it →
What the company does: Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

📈 Repligen (RGEN) stock price

$175.42+18.2% over range
Oct 14, 25low $102.87 · high $194.57Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
89% recommend buying · 9 analysts
📊 JPI status : Repligen has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Buy” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 RGEN price target & analyst consensus — price $175

The price target · all analysts combined (9 targets)
Highest target · 2 firms of 9$225+28.3%
Median target · of 9 targets$175-0.2%
Lowest target · 1 firm of 9$145-17.3%
Current price$175.42
Where these 9 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 444% $185 ↔ $225
Below 556% $145 ↔ $175
⏳ Targets haven't kept up with the price. 89% of ratings say “Buy”, yet 5 of 9 targets sit below the current price: the stock has risen past what analysts were aiming for, and some haven't raised their target yet. Read it as a dated view, not as a forecast of a drop.
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 64% of its targets hit on this sector (124 calls tested). It aims for $225 (+28 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).

The 3 reliable analysts $185+5.5 %
The 6 other firms $160-8.8 %
How to read it: the 3 reliable firms are not filtered by optimism — 2 aim above the price, 1 below, hence their $185 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 9 ratings (last 6 months)
Strong Buy00%
Buy889%
Hold111%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Repligen? The JPI assistant answers using our backtest data.

📈 Repligen fundamentals: valuation, margins & growth › open the full page

P/E 240.3Net margin 5.3 %Revenue growth +11.9 %Very expensive vs its growth

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 23 %
2023
Rev −20%Profit −78%
2024
Rev −1%Profit −161%
2025
Rev +16%

🔎 Detailed analyses

✅ Historical analyst reliability on RGEN

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Citigroup ↗ 100% +78.0% 2
Evercore ISI Group ↗ 100% +28.5% 2
Barclays ↗ 100% +18.7% 2
Stifel ↗ 86% +54.7% 7
Jefferies ↗ 80% +69.3% 5
HC Wainwright & Co. ↗ 58% +27.3% 12
Keybanc ↗ 43% -5.4% 7
Stephens & Co. ↗ 40% +10.5% 5
Wells Fargo ↗ 33% -5.7% 3
Craig-Hallum ↗ 33% -10.3% 3
See the other 4 firms
UBS ↗ 0% -15.4% 3
RBC Capital ↗ 20% -9.8% 10
JP Morgan ↗ 25% +0.4% 8
SVB Leerink 29% -1.2% 7

📊 What $1,000 invested in Repligen would be worth › open the full page

In short — $1,000 invested in Repligen 10 years ago would be worth $4,823 today, i.e. +17%/yr on average. Best year: 2020 (+107%), worst: 2022 (-36%). Price performance, excluding dividends.

If I'd invested $1,000 in Repligen

InvestmentWorth todayGain
1 years ago$948-5%
3 years ago$806-19%
5 years ago$712-29%
→ See Repligen's full return history + gain calculator

Return by year (Repligen)

YearReturn$1,000 invested at year start
2026 (YTD)-17%$833 (-17%)
2025+14%$948 (-5%)
2024-20%$759 (-24%)
→ See Repligen's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Repligen

Loading news…

📋 All analyst calls on RGEN

Barclays ↗
Oct 7, 26
▲ Overweight · 🎯$225
Price at call : $163.84 — upside +37%
Today : $175.42 — upside +28%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Oct 7, 27
UBS ↗
Sep 9, 26
▲ Buy · 🎯$225
Price at call : $164.68 — upside +37%
Today : $175.42 — upside +28%
🎯 on RGEN : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 9, 27
Wells Fargo ↗
Jul 30, 26
▲ Overweight · 🎯$185
Price at call : $141.01 — upside +31%
Today : $175.42 — upside +5%
🎯 on RGEN : 50% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Jul 30, 27
JP Morgan ↗
Jul 29, 26
▲ Overweight · 🎯$175
Price at call : $143.6 — upside +22%
Today : $175.42 — upside -0%
🎯 on RGEN : 0% (3 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Jul 29, 27
Benchmark ↗
Jul 7, 26
▲ Buy · 🎯$185
Price at call : $139.83 — upside +32%
Today : $175.42 — upside +5%
🎯 on RGEN : no call matured yet · 📊 on Health : 72.7% · +19.3% (11 calls)
in progress (365j)
matures : Jul 7, 27
▲ Outperform · 🎯$160
Price at call : $139.83 — upside +14%
Today : $175.42 — upside -9%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Jul 6, 27
HSBC ↗
Jun 3, 26
▲ Buy · 🎯$150
Price at call : $126.55 — upside +19%
Today : $175.42 — upside -14%
🎯 on RGEN : 100% (1 call matured) · 📊 on Health : 50% · +7.0% (4 calls)
in progress (365j)
matures : Jun 3, 27
JP Morgan ↗
May 6, 26
▲ Overweight · 🎯$165
Price at call : $126.43 — upside +31%
Today : $175.42 — upside -6%
🎯 on RGEN : 0% (3 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : May 6, 27
See the other 49 calls, newest to oldest
Barclays ↗
May 6, 26
▲ Overweight · 🎯$160
Price at call : $126.43 — upside +27%
Today : $175.42 — upside -9%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : May 6, 27
■ Hold neutral · not a buy · 🎯$145
Price at call : $132.7 — gap to target +9%
Today : $175.42 — gap to target -17%
🎯 on RGEN : no call matured yet · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Apr 20, 27
Roth Capital
Apr 17, 26
▲ Buy · 🎯$160
Price at call : $131.99 — upside +21%
Today : $175.42 — upside -9%
🎯 on RGEN : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Apr 17, 27
Barclays ↗
Apr 14, 26
▲ Overweight · 🎯$145
Price at call : $131.93 — upside +10%
Today : $175.42 — upside -17%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Apr 14, 27
▲ Outperform · 🎯$140
Price at call : $115.29 — upside +21%
Today : $175.42 — upside -20%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Apr 6, 27
▲ Buy · 🎯$208
Price at call : $116.35 — upside +79%
Today : $175.42 — upside +19%
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Mar 23, 27
UBS ↗
Feb 25, 26
▲ Buy · 🎯$195
Price at call : $133.65 — upside +46%
Today : $175.42 — upside +11%
🎯 on RGEN : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Feb 25, 27
Barclays ↗
Feb 25, 26
▲ Overweight · 🎯$175
Price at call : $133.65 — upside +31%
Today : $175.42 — upside -0%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Feb 25, 27
Wells Fargo ↗
Feb 25, 26
▲ Overweight · 🎯$180
Price at call : $133.65 — upside +35%
Today : $175.42 — upside +3%
🎯 on RGEN : 50% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 25, 27
▲ Outperform · 🎯$170
Price at call : $132.14 — upside +29%
Today : $175.42 — upside -3%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Feb 25, 27
UBS ↗
Jan 16, 26
▲ Buy · 🎯$200
Price at call : $163.33 — upside +22%
Today : $175.42 — upside +14%
🎯 on RGEN : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Jan 16, 27
Barclays ↗
Dec 15, 25
▲ Overweight · 🎯$200
Price at call : $158.09 — upside +27%
Today : $175.42 — upside +14%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Dec 15, 26
Wells Fargo ↗
Dec 15, 25
▲ Overweight · 🎯$190
Price at call : $158.09 — upside +20%
Today : $175.42 — upside +8%
🎯 on RGEN : 50% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Dec 15, 26
■ Hold neutral · not a buy · 🎯$165
Price at call : $144.57 — gap to target +14%
Today : $175.42 — gap to target -6%
🎯 on RGEN : no call matured yet · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Oct 29, 26
Barclays ↗
Oct 29, 25
▲ Overweight · 🎯$175
Price at call : $144.57 — upside +21%
Today : $175.42 — upside -0%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
in progress (365j)
matures : Oct 29, 26
▲ Outperform · 🎯$175
Price at call : $150.81 — upside +16%
Today : $175.42 — upside -0%
Expected +16% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+8.6%
stock +9% · XLV +16%
matured Oct 7, 26
Barclays ↗
Oct 2, 25
▲ Overweight · 🎯$160
Price at call : $145.23 — upside +10%
Today : $175.42 — upside -9%
Expected +10% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+25.1%
stock +25% · XLV +16%
matured Oct 2, 26
HSBC ↗
Oct 1, 25
▲ Buy · 🎯$150
Price at call : $145.23 — upside +3%
Today : $175.42 — upside -14%
Expected +3% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 100% (1 call matured) · 📊 on Health : 50% · +7.0% (4 calls)
+25.1%
stock +25% · XLV +16%
matured Oct 1, 26
▲ Outperform · 🎯$155
Price at call : $125.94 — upside +23%
Today : $175.42 — upside -12%
Expected +23% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
+48.3%
stock +48% · XLV +24%
matured Sep 22, 26
Jefferies ↗
Sep 12, 25
■ Hold neutral · not a buy · 🎯$135
Price at call : $113.54 — gap to target +19%
Today : $175.42 — gap to target -23%
🎯 on RGEN : no call matured yet · 📊 on Health : 48.3% · +10.7% (116 calls)
in progress (365j)
matures : Sep 12, 26
▲ Buy · 🎯$180
Price at call : $116.18 — upside +55%
Today : $175.42 — upside +3%
Expected +55% · Actual +46% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+46.0%
stock +46% · XLV +27%
matured Sep 3, 26
RBC Capital ↗
Jul 30, 25
▲ Outperform · 🎯$204
Price at call : $117.07 — upside +74%
Today : $175.42 — upside +16%
Expected +74% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 25% (4 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+20.4%
stock +20% · XLV +25%
matured Jul 30, 26
Wells Fargo ↗
Jul 30, 25
▲ Overweight · 🎯$175
Price at call : $117.07 — upside +49%
Today : $175.42 — upside -0%
Expected +49% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 50% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
+20.4%
stock +20% · XLV +25%
matured Jul 30, 26
■ In-Line neutral · not a buy · 🎯$130
Price at call : $128.56 — gap to target +1%
Today : $175.42 — gap to target -26%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Jul 8, 26
Barclays ↗
Jun 24, 25
▲ Overweight · 🎯$150
Price at call : $123.35 — upside +22%
Today : $175.42 — upside -14%
Expected +22% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 48.3% · +1.1% (203 calls)
+12.2%
stock +12% · XLV +15%
matured Jun 24, 26
▲ Buy · 🎯$180
Price at call : $140.92 — upside +28%
Today : $175.42 — upside +3%
Expected +28% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-10.9%
stock -11% · XLV +5%
matured May 5, 26
RBC Capital ↗
Apr 30, 25
▲ Outperform · 🎯$189
Price at call : $137.2 — upside +38%
Today : $175.42 — upside +8%
Expected +38% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 25% (4 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-14.6%
stock -15% · XLV +6%
matured Apr 30, 26
JP Morgan ↗
Apr 29, 25
▲ Overweight · 🎯$190
Price at call : $137.99 — upside +38%
Today : $175.42 — upside +8%
Expected +38% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 0% (3 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-14.3%
stock -14% · XLV +4%
matured Apr 29, 26
■ Hold neutral · not a buy · 🎯$150
Price at call : $130 — gap to target +15%
Today : $175.42 — gap to target -14%
🎯 on RGEN : no call matured yet · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Apr 16, 26
■ In-Line neutral · not a buy · 🎯$155
Price at call : $144.34 — gap to target +7%
Today : $175.42 — gap to target -12%
🎯 on RGEN : 100% (2 calls matureds) · 📊 on Health : 39.1% · -4.9% (46 calls)
in progress (365j)
matures : Mar 18, 26
RBC Capital ↗
Feb 21, 25
▲ Outperform · 🎯$205
Price at call : $164.74 — upside +24%
Today : $175.42 — upside +17%
Expected +24% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 25% (4 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-17.8%
stock -18% · XLV +7%
matured Feb 21, 26
JP Morgan ↗
Feb 21, 25
▲ Overweight · 🎯$200
Price at call : $164.74 — upside +21%
Today : $175.42 — upside +14%
Expected +21% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 0% (3 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-17.8%
stock -18% · XLV +7%
matured Feb 21, 26
▲ Buy · 🎯$180
Price at call : $158.99 — upside +13%
Today : $175.42 — upside +3%
Expected +13% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-14.8%
stock -15% · XLV +8%
matured Feb 21, 26
■ Hold neutral · not a buy · 🎯$170
Price at call : $158.99 — gap to target +7%
Today : $175.42 — gap to target -3%
🎯 on RGEN : no call matured yet · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Feb 21, 26
▲ Buy · 🎯$180
Price at call : $167.9 — upside +7%
Today : $175.42 — upside +3%
Expected +7% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-3.3%
stock -3% · XLV +9%
matured Jan 23, 26
▲ Buy · 🎯$180
Price at call : $166.84 — upside +8%
Today : $175.42 — upside +3%
Expected +8% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+0.7%
stock +1% · XLV +11%
matured Jan 22, 26
■ Hold neutral · not a buy · 🎯$165
Price at call : $147.34 — gap to target +12%
Today : $175.42 — gap to target -6%
🎯 on RGEN : no call matured yet · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Dec 17, 25
Wolfe Research ↗
Nov 14, 24
■ Peer Perform neutral · not a buy
🎯 on RGEN : no call matured yet · 📊 on Health : 46.2% · +2.9% (13 calls)
in progress (365j)
matures : Nov 14, 25
RBC Capital ↗
Sep 26, 24
▲ Outperform · 🎯$205
Price at call : $145.93 — upside +40%
Today : $175.42 — upside +17%
Expected +40% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 25% (4 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-15.0%
stock -15% · XLV -11%
matured Sep 26, 25
Wells Fargo ↗
Aug 28, 24
▲ Overweight · 🎯$180
Price at call : $145.43 — upside +24%
Today : $175.42 — upside +3%
Expected +24% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 50% (2 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
-16.0%
stock -16% · XLV -12%
matured Aug 28, 25
Benchmark ↗
Aug 5, 24
■ Hold neutral · not a buy
🎯 on RGEN : no call matured yet · 📊 on Health : 72.7% · +19.3% (11 calls)
in progress (365j)
matures : Aug 5, 25
JP Morgan ↗
Jul 31, 24
▲ Overweight · 🎯$200
Price at call : $165.67 — upside +21%
Today : $175.42 — upside +14%
Expected +21% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 0% (3 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-28.2%
stock -28% · XLV -13%
matured Jul 31, 25
▲ Buy · 🎯$240
Price at call : $194.81 — upside +23%
Today : $175.42 — upside +37%
Expected +23% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-18.6%
stock -19% · XLV +6%
matured May 5, 22
▲ Buy · 🎯$225
Price at call : $207.02 — upside +9%
Today : $175.42 — upside +28%
Expected +9% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-24.3%
stock -24% · XLV +17%
matured Apr 12, 22
▲ Buy · 🎯$168
Price at call : $145.99 — upside +15%
Today : $175.42 — upside -4%
Expected +15% · Actual +85% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+85.2%
stock +85% · XLV +28%
matured Aug 24, 21
▲ Buy · 🎯$151
Price at call : $123.61 — upside +22%
Today : $175.42 — upside -14%
Expected +22% · Actual +61% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+61.5%
stock +61% · XLV +26%
matured Jun 30, 21
▲ Buy · 🎯$143
Price at call : $122.25 — upside +17%
Today : $175.42 — upside -18%
Expected +17% · Actual +54% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+53.6%
stock +54% · XLV +25%
matured May 7, 21
▲ Buy · 🎯$100
Price at call : $94.68 — upside +6%
Today : $175.42 — upside -43%
Expected +6% · Actual +100% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+99.7%
stock +100% · XLV +42%
matured Mar 23, 21
▲ Buy
Actual +53% · Reason (≥ +15%) : ✓ Yes
🎯 on RGEN : 58% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+52.9%
stock +53% · XLV +16%
matured Jul 21, 20

Frequently asked questions

Should I buy Repligen stock?

This isn't buy advice. For Repligen, the analyst consensus is "Buy", with an average price target of $175 (0% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Repligen). We show the numbers — you decide.

Is it too late to buy Repligen? How high can it go?

The most bullish analyst target on Repligen is $225 (+28% above today's price); the average is $175. That's the upside they see. Check how reliable those analysts have actually been on Repligen on our site before trusting it.

Is Repligen still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 14 analysts have a real record on Repligen, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Repligen? The case for and against

The arguments for and against, one by one, from the numbers: why invest in RGEN (and why hesitate).

What has Repligen's past performance been?

Historical returns and a "how much if I had invested" calculator: RGEN performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)